Literature DB >> 16436691

Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis.

Fred Widmer1, Lesley C Wright, Daniel Obando, Rosemary Handke, Ranjini Ganendren, David H Ellis, Tania C Sorrell.   

Abstract

The alkyl phosphocholine drug miltefosine is structurally similar to natural substrates of the fungal virulence determinant phospholipase B1 (PLB1), which is a potential drug target. We determined the MICs of miltefosine against key fungal pathogens, correlated antifungal activity with inhibition of the PLB1 activities (PLB, lysophospholipase [LPL], and lysophospholipase-transacylase [LPTA]), and investigated its efficacy in a mouse model of disseminated cryptococcosis. Miltefosine inhibited secreted cryptococcal LPTA activity by 35% at the subhemolytic concentration of 25 microM (10.2 microg/ml) and was inactive against mammalian pancreatic phospholipase A2 (PLA2). At 250 microM, cytosolic PLB, LPL, and LPTA activities were inhibited by 25%, 51%, and 77%, respectively. The MICs at which 90% of isolates were inhibited (MIC90s) against Candida albicans, Candida glabrata, Candida krusei, Cryptococcus neoformans, Cryptococcus gattii, Aspergillus fumigatus, Fusarium solani, Scedosporium prolificans, and Scedosporium apiospermum were 2 to 4 microg/ml. The MICs of miltefosine against Candida tropicalis (n = 8) were 2 to 4 microg/ml, those against Aspergillus terreus and Candida parapsilosis were 8 microg/ml (MIC90), and those against Aspergillus flavus (n = 8) were 2 to 16 microg/ml. Miltefosine was fungicidal for C. neoformans, with rates of killing of 2 log units within 4 h at 7.0 microM (2.8 microg/ml). Miltefosine given orally to mice on days 1 to 5 after intravenous infection with C. neoformans delayed the development of illness and mortality and significantly reduced the brain cryptococcal burden. We conclude that miltefosine has broad-spectrum antifungal activity and is active in vivo in a mouse model of disseminated cryptococcosis. The relatively small inhibitory effect on PLB1 enzyme activities at concentrations exceeding the MIC by 2 to 20 times suggests that PLB1 inhibition is not the only mechanism of the antifungal effect.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436691      PMCID: PMC1366877          DOI: 10.1128/AAC.50.2.414-421.2006

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  37 in total

1.  Choline transport in Leishmania major promastigotes and its inhibition by choline and phosphocholine analogs.

Authors:  Rachel Zufferey; Choukri Ben Mamoun
Journal:  Mol Biochem Parasitol       Date:  2002 Nov-Dec       Impact factor: 1.759

2.  Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues.

Authors:  H Lux; D T Hart; P J Parker; T Klenner
Journal:  Adv Exp Med Biol       Date:  1996       Impact factor: 2.622

3.  Miltefosine Zentaris.

Authors:  Ronald Kaminsky
Journal:  Curr Opin Investig Drugs       Date:  2002-04

4.  Purification and characterization of secretory phospholipase B, lysophospholipase and lysophospholipase/transacylase from a virulent strain of the pathogenic fungus Cryptococcus neoformans.

Authors:  S C Chen; L C Wright; J C Golding; T C Sorrell
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

5.  Effects of miltefosine on various biochemical parameters in a panel of tumor cell lines with different sensitivities.

Authors:  M Rybczynska; M Spitaler; N G Knebel; G Boeck; H Grunicke; J Hofmann
Journal:  Biochem Pharmacol       Date:  2001-09-15       Impact factor: 5.858

6.  Oral miltefosine for Indian visceral leishmaniasis.

Authors:  Shyam Sundar; T K Jha; C P Thakur; Juergen Engel; Herbert Sindermann; Christina Fischer; Klaus Junge; Anthony Bryceson; Jonathan Berman
Journal:  N Engl J Med       Date:  2002-11-28       Impact factor: 91.245

7.  Ether--lipid (alkyl-phospholipid) metabolism and the mechanism of action of ether--lipid analogues in Leishmania.

Authors:  H Lux; N Heise; T Klenner; D Hart; F R Opperdoes
Journal:  Mol Biochem Parasitol       Date:  2000-11       Impact factor: 1.759

8.  Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans.

Authors:  G M Cox; H C McDade; S C Chen; S C Tucker; M Gottfredsson; L C Wright; T C Sorrell; S D Leidich; A Casadevall; M A Ghannoum; J R Perfect
Journal:  Mol Microbiol       Date:  2001-01       Impact factor: 3.501

9.  Evidence of multiple extracellular phospholipase activities of Aspergillus fumigatus.

Authors:  M Birch; G Robson; D Law; D W Denning
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  Purification and characterization of lysophospholipase-transacylase (h-LPTA) from a highly virulent strain of Candida albicans.

Authors:  F Mirbod; Y Banno; M A Ghannoum; A S Ibrahim; S Nakashima; Y Kitajima; G T Cole; Y Nozawa
Journal:  Biochim Biophys Acta       Date:  1995-07-13
View more
  33 in total

1.  In Vitro Activities of Miltefosine and Antibacterial Agents from the Macrolide, Oxazolidinone, and Pleuromutilin Classes against Pythium insidiosum and Pythium aphanidermatum.

Authors:  Erico S Loreto; Juliana S M Tondolo; Daniele C Oliveira; Janio M Santurio; Sydney H Alves
Journal:  Antimicrob Agents Chemother       Date:  2018-02-23       Impact factor: 5.191

Review 2.  The antifungal pipeline: a reality check.

Authors:  John R Perfect
Journal:  Nat Rev Drug Discov       Date:  2017-05-12       Impact factor: 84.694

3.  Miltefosine Has a Postantifungal Effect and Induces Apoptosis in Cryptococcus Yeasts.

Authors:  Cristina de Castro Spadari; Taissa Vila; Sonia Rozental; Kelly Ishida
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

4.  A P4-ATPase subunit of the Cdc50 family plays a role in iron acquisition and virulence in Cryptococcus neoformans.

Authors:  Guanggan Hu; Mélissa Caza; Erik Bakkeren; Matthias Kretschmer; Gaurav Bairwa; Ethan Reiner; James Kronstad
Journal:  Cell Microbiol       Date:  2017-01-23       Impact factor: 3.715

5.  In vitro combination of voriconazole and miltefosine against clinically relevant molds.

Authors:  S Imbert; M Palous; I Meyer; E Dannaoui; D Mazier; A Datry; A Fekkar
Journal:  Antimicrob Agents Chemother       Date:  2014-09-08       Impact factor: 5.191

6.  Ultrastructural analysis of miltefosine-induced surface membrane damage in adult Schistosoma mansoni BH strain worms.

Authors:  Humberto Gonçalves Bertão; Renata Alexandre Ramos da Silva; Rafael José R Padilha; Mônica Camelo Pessôa de Azevedo Albuquerque; Gandhi Rádis-Baptista
Journal:  Parasitol Res       Date:  2012-01-04       Impact factor: 2.289

7.  Miltefosine increases lipid and protein dynamics in Leishmania amazonensis membranes at concentrations similar to those needed for cytotoxicity activity.

Authors:  Rodrigo Alves Moreira; Sebastião Antonio Mendanha; Kelly Souza Fernandes; Grazzielle Guimaraes Matos; Lais Alonso; Miriam Leandro Dorta; Antonio Alonso
Journal:  Antimicrob Agents Chemother       Date:  2014-03-10       Impact factor: 5.191

8.  In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes.

Authors:  Zhongsheng Tong; Fred Widmer; Tania C Sorrell; Zofia Guse; Katrina A Jolliffe; Catriona Halliday; Ok Cha Lee; Fanrong Kong; Lesley C Wright; Sharon C A Chen
Journal:  Antimicrob Agents Chemother       Date:  2007-03-19       Impact factor: 5.191

9.  Evaluation of the effect of miltefosine on Trichomonas vaginalis.

Authors:  Débora Afonso Silva Rocha; Ivone de Andrade Rosa; Wanderley de Souza; Marlene Benchimol
Journal:  Parasitol Res       Date:  2013-12-22       Impact factor: 2.289

10.  Effect of therapeutic chemical agents in vitro and on experimental meningoencephalitis due to Naegleria fowleri.

Authors:  Jong-Hyun Kim; Suk-Yul Jung; Yang-Jin Lee; Kyoung-Ju Song; Daeho Kwon; Kyongmin Kim; Sun Park; Kyung-Il Im; Ho-Joon Shin
Journal:  Antimicrob Agents Chemother       Date:  2008-09-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.